KI
ALNY icon

Kula Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kula Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,242
Closed -$295K – 589
2022
Q4 		$295K Buy
+1,242
New +$265K 0.09% 389

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Kula Investments's ALNY Position: Q1 2023 in Review

Kula Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 1,242 shares — an estimated $295K sold.

Kula Investments first reported a position in ALNY in Q4 2022 and held it in 1 quarter. The position peaked at $295K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

  • Kula Investments reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Kula Investments sold 1,242 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $295K.
  • Kula Investments first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Kula Investments's Alnylam Pharmaceuticals position peaked at $295K in Q4 2022.
  • 476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.